Targeted therapy and handfoot skin reaction in advanced renal cell carcinoma

Chih Hsun Yang, Cheng Keng Chuang, Jia Juan Hsieh, John Wen Cheng Chang

Research output: Contribution to journalReview articlepeer-review

16 Scopus citations

Abstract

Importance of the field: Targeted therapy has significantly prolonged the survival of patients with advanced renal cell carcinoma (RCC). As first-line treatment, sunitinib, temsirolimus and bevacizumab plus IFN-α are demonstrated to prolong progression-free survival and/or overall survival. As second-line treatment, sorafenib was active mainly for patients in whom cytokine therapy failed. Recently, second-line treatment with everolimus has been shown to benefit patients progressing through tyrosine kinase inhibitors. Meanwhile, FDA has just approved pazopanib for the treatment of patients with advanced RCC. Various toxicities were associated with these agents. These toxicities were generally well tolerated. However, a high frequency of severe skin and bone marrow toxicities has been reported in Asian countries. Areas covered in this review: We have reviewed the literature of current targeted therapeutic agents and handfoot skin reaction (HFSR) in advanced RCC available in MEDLINE and meeting reports of ASCO, ECCO-ESMO and the 2009 Genitourinary Cancers Symposium. What the reader will gain: Readers will know of the efficacy and safety, including HFSR, of current targeted therapy. Take home message: Careful monitoring and appropriate management of the toxicities, especially HFSR, are needed.

Original languageEnglish
Pages (from-to)459-470
Number of pages12
JournalExpert Opinion on Drug Safety
Volume9
Issue number3
DOIs
StatePublished - 05 2010

Keywords

  • Handfoot skin reaction
  • Renal cell carcinoma
  • Targeted therapy
  • Tolerance

Fingerprint

Dive into the research topics of 'Targeted therapy and handfoot skin reaction in advanced renal cell carcinoma'. Together they form a unique fingerprint.

Cite this